Rapid Vertical Flow diagnostics manufacturer MedMira has obtained the CE mark for its Covid-19 test, which has been designed to identify the presence of total antibodies.
The REVEALCOVID-19 PLUS Total Antibody Test can detect antibodies that are generated from a prior infection or following vaccination against the SARS-CoV-2 virus.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
MedMira will now launch the test in Europe and other countries that accept the CE mark.
MedMira CEO Hermes Chan said: “We believe the REVEALCOVID-19 PLUS is our next step in Europe to support the healthcare system by allowing a more personalised responsibility approach by offering an easy testing tool and the quickest possible time.
“The use of our REVEALCOVID-19 PLUS will also give a great example of its quality and speed to our customers and open the path further for all our other products.
“During the various independent evaluations, we have received an overwhelming positive response on the quality and handling of our product, and we feel excited to launch this necessary and important product in Europe.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe test, which can be concluded in less than three minutes, is one out of four products for Covid-19 that MedMira has developed and manufactured exclusively at its internationally certified plant.
It provides results instantly and can be used in doctor’s offices and pharmacies due to its ease of use and speed.
In the coming weeks, the company plans to launch its second antibody product in Europe.
Complementing the REVEALCOVID-19 PLUS test, the second product will provide a better understanding of an individual’s potential protection against SARS-CoV-2.
